Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8113)	12/23/1998 10:55:00 AM
From: opalapril	Read Replies (2) \| Respond to of 17367

Is anyone else finding a paradox in Xoma's recent price action, given the company's openly avowed reasons for the Bermuda move? The proxy came as close as one supposes it could -- maybe too close, in fact -- to predicting FDA approval along the way of rationalizing the move to save taxes on projected profits. Profits, mind you! A word very few Earthlings would associate with Xoma. Yet, the stock price inches down, inches up, and generally continues its chronically sick behavior with absolutely no evidence of buying pressure. This does not look good, in my opinion. What's going on? Has FDA approval already been built into the anemic stock price? Is the company's proxy talk about profits just a massive head-fake? Hard to believe all the biotech investment fund managers on Wall Street are dumber than we are.